ETA
6.3.2024 13:41:28 CET | Business Wire | Press release
Cairo is transforming into a long weekend hotspot with the new City Break initiative, announced H.E. Ahmed Issa, the Minister of Tourism and Antiquities of Egypt at ITB Berlin 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306125956/en/
Minister Ahmed Issa at press conference, ITB Berlin 2024 (Photo: Business Wire)
Cairo City Break Program and A New Era of Luxury Tourism
The new Cairo City Break program is aimed at transforming the capital into a dynamic, must-visit long weekend destination. The visitors will have the opportunity to explore many tourist and archaeological sites by offering diverse and varied tourist experiences encompassing various historical and cultural places, whether Pharaonic, Coptic, or Islamic.
This will contribute to increasing the number of tourist nights spent in Cairo from an average of three to four days to 12 days.
“There is no other city that can offer visitors monuments from every great civilization starting from 3500 B.C. We are dedicated to turning Cairo into a destination that can be enjoyed over the span of multiple visits or a long weekend,” stated the Minister of Tourism and Antiquities, H.E. Ahmed Issa.
Egypt has also been actively developing emerging destinations and elevating traveler's experience at archaeological sites by introducing new destinations and improved, faster, and environmentally friendly ways of commute to key destinations such as Luxor. For instance, in Q4 2025/Q1 2026 Hurghada and Luxor will be connected by a high-speed train.
A Transformative Reform and Infrastructure Development
Egypt's tourism industry is undergoing a transformative reform towards deregulation, paving the way for new investors, and redefining the relationship between the government and the private sector. In tandem with the reform, Egypt’s strategic deregulation efforts and the allocation of 22% of GDP to infrastructure development over the past seven years are paying off, demonstrating a strong commitment to boosting the country's global tourism reputation. The aim is to double Egypt's hotel capacity to 60,000 rooms within the next five years.
Record-Breaking Tourism Results and Main Travel Trends
Egypt witnessed an extraordinary surge in tourism during 2023, with a record 14.906 million visitors gracing its shores — an exponential increase from the 4.9 million recorded in 2021.
This upward trend is expected to continue in 2024, with a remarkable 8% year-on-year growth in the first 50 days of the year. Most visitors come from Germany, with 1.6 million tourists recorded last year, followed by Russia, Saudi Arabia, Italy, and the United Kingdom.
About the Egyptian Tourism Authority
Established in 1981, the Egyptian Tourism Authority is dedicated to promoting Egypt's vast historical assets and diverse destinations, fostering domestic tourism, and connecting Egyptians with their rich heritage. Under the leadership of the Minister of Tourism, the Egyptian Tourism Authority spearheads marketing strategies, supports tourism development, and sponsors various events to enhance Egypt's tourism industry.
For more information, visit Experience Egypt.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306125956/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
